HNRNPA1P35: A Potential Drug Target Or Biomarker (G645691)

Target Name: HNRNPA1P35

NCBI ID: G645691

HNRNPA1P35

Other Name(s): heterogeneous nuclear ribonucleoprotein A1 pseudogene 35 | Heterogeneous nuclear ribonucleoprotein A1 pseudogene 35

HNRNPA1P35: A Potential Drug Target Or Biomarker

HNRNPA1P35, also known as heterogeneous nuclear ribonucleoprotein A1 pseudogene 35, is a gene that has been identified as a potential drug target or biomarker. The protein encoded by this gene is a key component of the nuclear ribonucleoprotein complex, which is a protein complex that plays a critical role in the regulation of gene expression. Mutations in the HNRNPA1P35 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The HNRNPA1P35 gene is located on chromosome 16 and encodes a protein of 21 kDa. This protein is composed of multiple domains, including an N-terminus, a catalytic domain, and a C-terminus. The N-terminus of the protein contains a putative RNA binding domain that is known to interact with various RNA molecules. The catalytic domain of the protein contains a catalytic site that is optimized for the activity of RNA binding proteins. The C-terminus of the protein contains a polyglutamic acid (PGA) tail, which is known to play a role in the stability and stability of the protein.

HNRNPA1P35 has been shown to play a critical role in the regulation of gene expression in various organisms, including humans. For example, studies have shown that HNRNPA1P35 is involved in the regulation of gene expression in cancer cells. In addition, HNRNPA1P35 has also been shown to be involved in the regulation of gene expression in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Due to its involvement in the regulation of gene expression, HNRNPA1P35 has been identified as a potential drug target or biomarker. Researchers are currently working to develop small molecules that can modulate the activity of HNRNPA1P35 and enhance its ability to interact with RNA binding proteins. These Small molecules may be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, HNRNPA1P35 is a gene that has been identified as a potential drug target or biomarker due to its involvement in the regulation of gene expression. Further research is needed to understand the full role of HNRNPA1P35 in the regulation of gene expression and to develop effective treatments for diseases associated with its dysfunction.

Protein Name: Heterogeneous Nuclear Ribonucleoprotein A1 Pseudogene 35

The "HNRNPA1P35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HNRNPA1P35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets